SEC Form 4 · accession 0000899243-18-024274
REPLIGEN CORP · RGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Hunt
Officer — Chief Executive Officer · Director
Period of report
Sep 10, 2018
Accepted (ET)
Sep 12, 2018 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000730272
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 10, 2018 | M | 11,873 | $16.55 | A | 255,017 | D | |
| Common StockF1,F2 | Sep 10, 2018 | S | 27,566 | $57.7091 | D | 227,451 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $16.55 | Sep 10, 2018 | M | 11,873 | D | — | May 5, 2024 | Common Stock | 11,873 | 38,127 | D |
Explanation of responses
- F1Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 17, 2017.
- F2$57.7091 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.18 to $58.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F310,000 shares vest and become exercisable on each of the following dates: 5/05/2015, 5/05/2016, 5/05/2017, 5/05/2018 and 5/05/2019.